Oncimmune gets lift from Scottish lung cancer study success


Oncimmune is a specialist in the field of immunodiagnostics


Quick facts: Oncimmune

Price: £0.90

Market: AIM
Market Cap: £56.93 m
  • Oncimmune's EarlyCDT test met its primary endpoint in a substantial study of lung cancer patients undertaken by the NHS

  • The primary endpoint was the difference, at 24 months after randomisation, between the rates of patients with stage III, IV or unclassified lung cancer

  • The company already has European CE mark approval for the EarlyCDT- Lung test and has 18 global agreements in place with a total minimum of £33.5mln sales

  • In May, the company also announced the start of a major trial in China to test for early-stage lung cancer

  • At 86.5p  share, Oncimmune is valued at £58mln


What the company does: 

Oncimmune PLC (LON:ONC) is a specialist in the field of immunodiagnostics.

Specifically, its technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis.

Founded in 2002, it launched its platform technology in 2009, followed by its first commercial tests - EarlyCDT-Lung and EarlyCDT-Liver.

To date, over 155,000 Oncimmune tests have been performed worldwide.

EarlyCDT-Lung was used in the largest-ever trial for the early detection of lung cancer using biomarkers - the National Health Service's Early Cancer Detection Test-Lung Cancer Scotland (ECLS) study of 12,210 high-risk smokers in Scotland.

Oncimmune also develops precision medicine and patient tools that allow doctors to place people being treated for cancer and autoimmune diseases into certain patient sub-groups, a process called stratification.

Scottish NHS study success:

A total of 12,210 Scots were monitored for two years as part of the ECLS initiative in what is believed to be the largest randomised controlled assessment of its kind.

Sponsored by the University of Dundee and NHS Tayside and co-funded by the Chief Scientist Office, the study, to use the scientific parlance, hit its primary end-point.

Specifically, monitoring recruits reduced the incidence of people with late-stage lung cancer, or “unclassified presentation at diagnosis”, compared to standard clinical practice.

What the boss says - Adam Hill, chief executive:

"Lung is the largest market in terms of unmet need in cancer diagnosis today.

“Of those detected, 75-80% are in the late stages where treatment options are limited and survival rates relatively poor.

"One way to tackle this is to detect it earlier in stages one or two, which gives better treatment options."


Inflexion Points

Last October, Oncimmune outlined a three-year strategy that will see the company focus on its core business of cancer early detection while looking for value- and revenue-enhancing partnerships and acquisitions.

In March it delivered on the acquisitions portion when it bought Protagen Diagnostics for up to £4.11mln-worth of shares. The deal will accelerate Oncimmune's biomarker discovery process and grow its development library to over 8,000 proteins.

Preparations are now underway in Scotland to conduct “a phased population-based” evaluation using EarlyCDT-Lung that would recruit 200,000 people.

The Oncimmune blood test would be supplied on “negotiated commercial terms”, the company said.

A submission of the full ECLS study findings will be made to an unnamed, peer-reviewed medical publication sometime in the next quarter.

And a late-breaking abstract is being prepared for the International Association for the Study of Lung Cancer World Conference on Lung Cancer on 7-10 September 2019 – the world’s largest lung cancer gathering.


Oncimmune CEO details multi-million-pound deal with Russia’s leading drugmaker

Adam Hill, chief executive of Oncimmune Holdings PLC (LON:ONC), talks Proactive London's Andrew Scott through a multi-million-pound deal they've signed which will see its EarlyCDT Lung cancer detection test used by Russia’s leading drugmaker. R-Pharm now has the exclusive right to use the...

on 5/7/19

3 min read